TRITON-PN:遺伝性トランスサイレチンアミロイドーシスによる多発神経障害を有する患者におけるヌクレシランの有効性と安全性を評価する研究 (TRITON-PN)
TRITON-PN:遺伝性トランスサイレチン介在アミロイドーシス多発神経障害(hATTR-PN)患者におけるヌクレシランの有効性と安全性を評価する第III相、国際的、無作為化、非盲検試験
The purpose of this study is to:
- Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed
- Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Clinical Trial Information Line
- 電話番号:1-877-ALNYLAM
- メール:clinicaltrials@alnylam.com
研究連絡先のバックアップ
- 名前:Clinical Trial Information Line
- 電話番号:1-877-256-9526
- メール:clinicaltrials@alnylam.com
研究場所
-
-
-
Dublin、アイルランド、D24 NR0A
- 募集
- Clinical Trial Site
-
-
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- 募集
- Clinical Trial Site
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- 募集
- Clinical Trial Site
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21287
- 募集
- Clinical Trial Site
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02118
- 募集
- Clinical Trial Site
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- 募集
- Clinical Trial Site
-
-
New York
-
New York、New York、アメリカ、10032
- 募集
- Clinical Trial Site
-
New York、New York、アメリカ、10016
- 募集
- Clinical Trial Site
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27514
- 募集
- Clinical Trial Site
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37232
- 募集
- Clinical Trial Site
-
-
Texas
-
Dallas、Texas、アメリカ、75246
- 募集
- Clinical Trial Site
-
Houston、Texas、アメリカ、77030
- 募集
- Clinical Trial Site
-
-
-
-
-
Belgrano、アルゼンチン、C1428AQK
- 募集
- Clinical Trial Site
-
Rosario、アルゼンチン、CP2000
- 募集
- Clinical Trial Site
-
-
-
-
-
London、イギリス、NW3 2QG
- 募集
- Clinical Trial Site
-
-
-
-
-
Florence、イタリア、50134
- 募集
- Clinical Trial Site
-
Milan、イタリア、20133
- 募集
- Clinical Trial Site
-
Padova、イタリア、35128
- 募集
- Clinical Trial Site
-
Pavia、イタリア、27100
- 募集
- Clinical Trial Site
-
Roma、イタリア、00168
- 募集
- Clinical Trial Site
-
-
-
-
-
Darlinghurst、オーストラリア、2010
- 募集
- Clinical Trial Site
-
Woolloongabba、オーストラリア、4102
- 募集
- Clinical Trial Site
-
-
-
-
-
Vancouver、カナダ、V5Z 1M9
- 募集
- Clinical Trial Site
-
-
-
-
-
Égkomi、キプロス、2371
- 募集
- Clinical Trial Site
-
-
-
-
-
Athens、ギリシャ、115 28
- 募集
- Clinical Trial Site
-
Heraklion、ギリシャ、715 00
- 募集
- Clinical Trial Site
-
-
-
-
-
Bern、スイス、3010
- 募集
- Clinical Trial Site
-
-
-
-
-
Stockholm、スウェーデン、113 61
- 募集
- Clinical Trial Site
-
Umeå、スウェーデン、907 37
- 募集
- Clinical Trial Site
-
-
-
-
-
Barcelona、スペイン、08035
- 募集
- Clinical Trial Site
-
Huelva、スペイン、21005
- 募集
- Clinical Trial Site
-
L'Hospitalet de Llobregat、スペイン、8907
- 募集
- Clinical Trial Site
-
Madrid、スペイン、28040
- 募集
- Clinical Trial Site
-
Palma de Mallorca、スペイン、07198
- 募集
- Clinical Trial Site
-
-
-
-
-
Istanbul、トルコ(Türkiye)、34093
- 募集
- Clinical Trial Site
-
Izmir、トルコ(Türkiye)、35330
- 募集
- Clinical Trial Site
-
-
-
-
-
Berlin、ドイツ、10117
- 募集
- Clinical Trial Site
-
Heidelberg、ドイツ、69120
- 募集
- Clinical Trial Site
-
Münster、ドイツ、48149
- 募集
- Clinical Trial Site
-
-
-
-
-
Créteil、フランス、94000
- 募集
- Clinical Trial Site
-
Le Kremlin-Bicêtre、フランス、94270
- 募集
- Clinical Trial Site
-
Marseille、フランス、13005
- 募集
- Clinical Trial Site
-
-
-
-
-
Ribeirão Preto、ブラジル、14051-140
- 募集
- Clinical Trial Site
-
Rio de Janeiro、ブラジル、22640-100
- 募集
- Clinical Trial Site
-
Rio de Janeiro、ブラジル、22775-001
- 募集
- Clinical Trial Site
-
Salvador、ブラジル、40290-000
- 募集
- Clinical Trial Site
-
São Paulo、ブラジル、04038-002
- 募集
- Clinical Trial Site
-
-
-
-
-
Lisbon、ポルトガル、1649-035
- 募集
- Clinical Trial Site
-
Porto、ポルトガル、4099-001
- 募集
- Clinical Trial Site
-
-
-
-
-
Kuala Lumpur、マレーシア、59100
- 募集
- Clinical Trial Site
-
-
-
-
-
Guadalajara、メキシコ、44670
- 募集
- Clinical Trial Site
-
Tlalpan、メキシコ、14080
- 募集
- Clinical Trial Site
-
-
-
-
-
Taipei、台湾、10002
- 募集
- Clinical Trial Site
-
Taipei、台湾、112
- 募集
- Clinical Trial Site
-
Taoyuan City、台湾、33305
- 募集
- Clinical Trial Site
-
-
-
-
-
Bunkyo C、日本、113-8519
- 募集
- Clinical Trial Site
-
Kumamoto、日本、860-8556
- 募集
- Clinical Trial Site
-
Matsumoto-shi、日本、390-8621
- 募集
- Clinical Trial Site
-
Suita、日本、565-0871
- 募集
- Clinical Trial Site
-
-
-
-
-
Seoul、韓国、06351
- 募集
- Clinical Trial Site
-
Seoul、韓国、05030
- 募集
- Clinical Trial Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Has documented diagnosis of hATTR-PN
- Has a diagnosis of hATTR amyloidosis with polyneuropathy with a documented TTR gene variant
- Has a neuropathy impairment score (NIS) of 5 to 130 (inclusive)
- Has a Karnofsky Performance Status (KPS) of ≥60%
Exclusion Criteria:
- Has had a liver transplant or is likely, in the opinion of the Investigator, to undergo liver transplantation during the Treatment Period of the study
- Has known other (non-hATTR) forms of amyloidosis or clinical evidence of leptomeningeal amyloidosis
- Has a New York Heart Association (NYHA) heart failure classification >2
- Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 upper limit of normal (ULN)
- Has total bilirubin >1.5 ULN
- Has estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73m^2
- Has other known causes of sensorimotor or autonomic neuropathy
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Nucresiran 300 mg
Patients will be administered nucresiran 300 mg subcutaneously (SC) once every 6 months (q6M) during the Treatment Period and Treatment Extension Period |
Nucresiran 300 mg administered SC q6M
他の名前:
|
|
アクティブコンパレータ:Vutrisiran 25 mg followed by Nucresiran 300 mg
Patients will be administered vutrisiran 25 mg SC every 3 months (q3M) during the Treatment Period followed by nucresiran 300 mg SC q6M during the Treatment Extension Period |
Nucresiran 300 mg administered SC q6M
他の名前:
Vutrisiran 25 mg administered SC q3M
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from Baseline in the Modified Neuropathy Impairment Score +7 (mNIS+7) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
時間枠:Baseline and Month 9
|
The mNIS+7 is a composite score that measures neurologic impairment which includes the following components: physical exam of lower limbs, upper limbs and cranial nerves to assess motor strength/weakness and deep tendon reflexes, electrophysiologic measurement of large nerve fiber function, sensory testing and postural blood pressure. The mNIS+7 is scored from 0 (no impairment) to 304 points (maximum impairment). A higher score indicates a worse outcome. |
Baseline and Month 9
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
ヌクレシラン群における血清TTRレベル9ヶ月時点での院内ビュートリシラン群との比較における割合減少
時間枠:最大9ヶ月
|
最大9ヶ月
|
|
|
ヌクレシラン群における血清TTRレベルのパーセント減少(18か月時点での研究内ブトリシラン群との比較)
時間枠:最大18か月
|
最大18か月
|
|
|
ヌクレシラン群における血清TTRレベルの6週目での研究内ブトリシラン群との比較における減少率
時間枠:第6週
|
第6週
|
|
|
Change from Baseline in Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) Total Score Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
時間枠:Baseline and Month 9
|
The Norfolk QoL-DN is a standardized 35-item patient-rated questionnaire used to assess 5 domains: physical function, large fiber neuropathy, activities of daily living, symptoms, small fiber neuropathy, and autonomic neuropathy. The minimum and maximum values are -4 and 136, respectively. A higher score indicates a worse outcome. |
Baseline and Month 9
|
|
Change from Baseline in Modified Body Mass Index (mBMI) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
時間枠:Baseline and Month 9
|
The mBMI, which is a measure of nutritional status, is calculated as the product of body mass index (BMI) (weight in kilograms divided by the square of height in meters) and serum albumin (g/L) to reflect fluid balance, such as fluid accumulation or dehydration. A negative change from baseline indicates a better outcome. |
Baseline and Month 9
|
|
Change from Baseline in the mNIS+7 Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
時間枠:Baseline and Month 18
|
The mNIS+7 is a composite score that measures neurologic impairment which includes the following components: physical exam of lower limbs, upper limbs and cranial nerves to assess motor strength/weakness and deep tendon reflexes, electrophysiologic measurement of large nerve fiber function, sensory testing and postural blood pressure. The mNIS+7 is scored from 0 (no impairment) to 304 points (maximum impairment). A higher score indicates a worse outcome. |
Baseline and Month 18
|
|
Change from Baseline in Norfolk QoL-DN Total Score Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
時間枠:Baseline and Month 18
|
The Norfolk QoL-DN is a standardized 35-item patient-rated questionnaire used to assess 5 domains: physical function, large fiber neuropathy, activities of daily living, symptoms, small fiber neuropathy, and autonomic neuropathy. The minimum and maximum values are -4 and 136, respectively. A higher score indicates a worse outcome. |
Baseline and Month 18
|
|
Change from Baseline in mBMI Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
時間枠:Baseline and Month 18
|
The mBMI, which is a measure of nutritional status, is calculated as the product of body mass index (BMI) (weight in kilograms divided by the square of height in meters) and serum albumin (g/L) to reflect fluid balance, such as fluid accumulation or dehydration. A negative change from baseline indicates a better outcome. |
Baseline and Month 18
|
|
Change from Baseline in Rasch-built Overall Disability Scale (R-ODS) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
時間枠:Baseline and Month 18
|
The R-ODS is a patient-reported measure of level of disability on a scale of 0-48, with 0 being the worst and 48 the best (no limitations); scores are based on activities of daily living and social participation. An increase in R-ODS from baseline suggests improvement in disability, and a decrease from baseline suggests worsening of disability. |
Baseline and Month 18
|
|
Change from Baseline in Timed 10-meter Walk Test (10-MWT) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
時間枠:Baseline and Month 18
|
The timed 10-MWT is a measure of ambulatory ability and measures the time (in seconds) that it takes a participant to walk 10 meters (gait speed). An increase in gait speed from baseline represents improvement, and a decrease from baseline represents worsening. |
Baseline and Month 18
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Medical Director、Alnylam Pharmaceuticals
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- ALN-TTRSC04-004
- 2025-522544-40-00 (Ctis)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Phase 2-4 trials:
Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU.
Access to data may be declined where there is likelihood a patient could be identified or other feasibility issue, where there is a potential conflict of interest, a planned business activities or an actual or potential competitive risk. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Timeframes for data access may vary and can take up to 6 months or more.
Requests for access to data can be submitted via the website www.vivli.org. Questions can also be directed to datasharing@alnylam.com.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。